Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

Korábbi kezelés

• Combined organ transplant history (including bone marrow autotransplantation and peripheral stem cell transplantation).

Más betegség

• Combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies.
• Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs.
• Combination of severe brain or mental illness that affects the patient's ability to self-report.

Egyéb

• Unable to complete the baseline assessment form
• Pregnant or lactating women.
• Combination of other uncontrolled tumors.
• Those who are legally incompetent and whose medical or ethical reasons affect the continuation of the research.

• Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.
• Presence of bone metastases.
• EGFR/ALK gene wild type.
• No prior treatment with PD-1 inhibitors (combination or monotherapy)
• Those who have not received prior antitumor therapy or have not received further antitumor therapy after failure of first-line antitumor therapy.
• PS score (ECOG) ≤ 2 points
• Normal hepatic and renal function.
  • Normal hepatic function: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value(ULN), serum serum aspartate aminotransferase(AST) \& alanine aminotransferase(ALT) ≤ 2.5 times ULN
  • Normal renal function: serum creatinine ≤ 1.5 mg/dl (133 μmol/L) and/or creatinine clearance ≥ 60 ml/min.
• Presence of at least one assessable lesion.
• Signed informed consent, patient willing to accept this regimen, able to adhere to the medication, and good compliance.